Australia’s ChemGenex Looks To Leukemia Drug For First Profits
This article was originally published in PharmAsia News
Australia's ChemGenex Pharmaceutical expects to win U.S. FDA approval next year for a leukemia drug derived from the leaves of a Chinese evergreen tree. The omacetaxine drug, now in Phase III trials, could provide ChemGenex with its first profits. The drug is seen as an alternative to the popular Novartis drug Gleevec (imatinib mesylate), to which some patients become resistant. The ChemGenex version is based on blocking a protein responsible for the disease. (Click here for more
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.